

Massy – November 5th, 2014

Publication of an independent equity research by Aurgalys

Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announces that Aurgalys, an equity research firm dedicated to life sciences, initiated the coverage of the company.

Their first financial analysis note, entitled «*Quantum Genomics could revolutionize the hypertension market*», is available on the website of Quantum Genomics (www.quantum-genomics.com), Investors section, and on Aurgalys website (www.aurgalys.com).

**Click on equity research
to consult it:**



About Quantum Genomics

Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.

Quantum Genomics is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than twenty years of academic research that has taken place in the laboratories of the Collège de France, INSERM and CNRS.

Quantum Genomics is listed on Alternext in Paris (ISIN code: FR0011648971 - ticker ALQGC).

Contacts

Quantum Genomics
Lionel Ségard
CEO
(+33) 1 60 13 76 80

Quantum Genomics
Marc Karako
CFO - Investor relations
(+33) 1 60 13 76 84
marc.karako@quantum-genomics.com

ACTUS
Jean-Michel Marmillon
Press relations
(33) 1 53 67 07 80
jmmarmillon@actus.fr